30-day average of 20 articles ยท scale โ100 to +100
Across 20 scored articles from Oct 17 to Nov 15, 2026 (UTC),
the average sentiment of AbbVie news is Bullish (+51)
on a scale from โ100 to +100.
That is about the same as the previous 30 days (+53).
๐ค AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion.
Bullish +62
AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
AI-generated analysis
Key insights
๐ AbbVie shares surged over 23% year-to-date, outperforming the S&P 500's roughly 13% gain as investors assess its transition strategy.
๐ Skyrizi and Rinvoq drove immunology revenue to $8.79 billion (up 15.1%), with Skyrizi up 24.4% and Rinvoq up 24.5%, offsetting a 35.9% decline in Humira.
๐ง The neuroscience portfolio delivered strong growth, increasing revenue by 20.3% to $3.23 billion in the second quarter.
๐ค AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion to bolster its immunology pipeline with late-stage candidate zumilokibart.
๐ฐ The company reported total second-quarter revenue of $16.99 billion (up 10.2%) and adjusted diluted EPS rose 22.9% on a reported basis.
โ ๏ธ Management expects the Apogee acquisition to have a $0.14 per share dilutive impact on 2026 adjusted EPS, alongside an unfavorable $0.58-per-share impact from acquired IPR&D expenses.
๐ AbbVie's forward P/E is approximately 16.4x, significantly lower than its trailing P/E of 74.88x due to non-recurring acquisition-related items affecting reported earnings.
๐ฎ The company expects 2026 adjusted diluted EPS between $13.87 and $14.07, following a revision to its July outlook.
๐ Humira revenue fell 35.9% to $756 million in the second quarter as AbbVie continues its portfolio transition away from the aging blockbuster.
๐ The Apogee acquisition is expected to close in the third quarter of 2026, adding clinical-stage immunology assets to the pipeline.
๐ Bullish signals
๐AbbVie shares surged over 23% year-to-date, significantly outperforming the broader market's roughly 13% gain.
๐Skyrizi and Rinvoq generated combined immunology revenue of $8.79 billion (up 15.1%), with individual growth rates of 24.4% and 24.5% respectively, effectively offsetting the decline in Humira.
๐ง The neuroscience portfolio demonstrated robust expansion with revenue increasing 20.3% to $3.23 billion in the second quarter.
๐ฐTotal company revenue increased 10.2% on a reported basis to $16.99 billion in the second quarter, while adjusted diluted EPS rose 22.9%.
๐ Risk factors
๐Humira revenue fell 35.9% to $756 million in the second quarter as the company continues its transition away from the aging blockbuster.
โ ๏ธThe acquisition of Apogee Therapeutics for approximately $10.9 billion will have a dilutive impact on 2026 adjusted EPS, including an unfavorable $0.58-per-share impact from acquired IPR&D expenses and an additional $0.14 per share dilution from the deal itself.
๐AbbVie's trailing P/E ratio is nearly 75x (74.88x), significantly higher than its forward P/E of 16.4x, indicating that reported earnings are currently depressed by significant acquisition-related and other specified items.
Article
AbbVie (NYSE: ABBV) has delivered strong returns in the first half of 2026, with shares surging over 23% year-to-date, significantly outperforming the broader market's roughly 13% gain. The company is currently trading at a forward P/E of approximately 16.4x, which analysts view as reasonable given its growth trajectory, though this contrasts sharply with its trailing P/E of nearly 75x due to significant acquisition-related and other specified items affecting reported earnings.
The core investment thesis for AbbVie centers on its ability to successfully transition away from the declining blockbuster Humira, which saw revenue fall 35.9% in the second quarter to $756 million. This decline has been effectively offset by robust growth in its newer immunology franchises: Skyrizi generated $5.505 billion (up 24.4%) and Rinvoq generated $2.53 billion (up 24.5%), bringing total global net revenue from the immunology portfolio to $8.79 billion, a 15.1% increase.
Beyond immunology, AbbVie's neuroscience portfolio showed particular strength with revenue increasing 20.3% to $3.23 billion in the second quarter. The company is also executing a major strategic expansion by acquiring Apogee Therapeutics for approximately $10.9 billion to add late-stage clinical assets like zumilokibart, expected to close in the third quarter of 2026. However, this acquisition and ongoing pipeline investment will have a dilutive impact on adjusted EPS, with management expecting an unfavorable $0.58-per-share impact from acquired IPR&D expenses and an additional $0.14 per share dilution from the Apogee deal itself.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Institutional investors have recently adjusted their positions in AbbVie Inc. (NYSE: ABBV), with AMG National Trust Bank increasing its stake by 20.2% to own 27,977 shares valued at $6.085 million in the first quarter. Other notable holders include Waycross Partners LLC, which owns 182,476 shares worth $41.694 million, and Calamos Advisors LLC, holding 466,290 shares valued at $106.543 million. Axecap Investments LLC significantly boosted its position by 713.2% to acquire 16,320 shares.
Wall Street analysts have issued mixed but generally positive ratings for the stock, with UBS raising its price target to $260 and Royal Bank of Canada increasing its target to $280. The consensus rating is a 'Moderate Buy' with an average price target of $266.24. However, Wall Street Zen recently downgraded the stock from a 'strong-buy' to a 'buy' rating, while DZ Bank upgraded it to a 'strong-buy'.
Financially, AbbVie reported Q1 earnings of $2.65 per share, beating analyst estimates of $2.59, with revenue reaching $15 billion, a 12.4% year-over-year increase. The company has a market capitalization of $438.27 billion and a PE ratio of 122.20. AbbVie also declared a quarterly dividend of $1.73 per share, payable on August 14th to shareholders of record on July 15th.
๐ AMG Trust Bank increased ABBV holdings by 20.2% in Q1.
๐ฐ UBS raised target to $260; RBC set target at $280.
๐ Wall Street Zen downgraded stock from 'strong-buy' to 'buy'.
๐ Q1 revenue hit $15B, beating estimates by $278 million.
๐ต EPS reached $2.65, surpassing the consensus of $2.59.
๐ AMG National Trust Bank increased its ABBV holdings by 20.2% in Q1, adding 4,710 shares.
๐ Institutional ownership of AbbVie stands at 70.23%, with Calamos Advisors holding the largest stake at 466,290 shares.
๐ฐ UBS raised its price target to $260 and Royal Bank of Canada increased its target to $280.
๐ Wall Street Zen downgraded ABBV from 'strong-buy' to 'buy' on July 5th.
๐ AbbVie reported Q1 revenue of $15 billion, beating estimates by $278 million.
๐ต The company posted EPS of $2.65, surpassing the consensus estimate of $2.59.
๐ Revenue grew 12.4% year-over-year compared to the prior period.
๐ธ AbbVie declared a quarterly dividend of $1.73 per share with an ex-dividend date of July 15th.
๐ The stock trades at a PE ratio of 122.20 with a market cap of $438.27 billion.
๐ฌ AbbVie focuses on therapies for complex conditions including immunology, oncology, and neuroscience.
Bullish Signals
Q1 revenue hit $15B, beating estimates by $278M.
EPS reached $2.65, surpassing consensus by $0.06.
Revenue grew 12.4% year-over-year in core segments.
UBS and RBC raised price targets to $260 and $280.
Institutional investors maintained or increased significant stakes.
Risk Factors
Downgraded from strong-buy to buy on July 5th.
High PE ratio of 122.20 indicates elevated valuation.
Bullish Signals
AbbVie reported Q1 revenue of $15 billion, which exceeded analyst estimates of $14.72 billion by $278 million.
The company posted earnings per share of $2.65, beating the consensus estimate of $2.59 by $0.06.
Revenue grew 12.4% year-over-year, demonstrating strong top-line growth in its core business segments.
Multiple major banks including UBS and Royal Bank of Canada have raised their price targets to $260 and $280 respectively.
Institutional investors like Calamos Advisors and Waycross Partners have maintained or increased significant stakes in the company.
Risk Factors
Wall Street Zen downgraded the stock from a 'strong-buy' rating to a 'buy' rating on July 5th.
The stock carries a high PE ratio of 122.20, which may indicate elevated valuation relative to current earnings.
Institutional investors have increased their stakes in AbbVie Inc. (NYSE: ABBV) during the first and second quarters of 2026, signaling renewed interest from hedge funds. Chicago Partners Investment Group LLC raised its position by 13.4% to own 58,582 shares valued at $11.7 million in Q1. Other notable increases include Worldquant Millennium Advisors LLC, which surged its holdings by 117.3% to acquire over 612,000 shares worth $210.6 million in Q2, and Revolve Wealth Partners LLC, which boosted its stake by 72.7%.
AbbVie recently reported strong quarterly financial results for the period ending April 29th, beating analyst expectations on both earnings per share and revenue. The company posted $2.65 EPS compared to a consensus of $2.59, driven by revenue of $15 billion which represented a 12.4% year-over-year increase. Despite the positive earnings beat, the stock trades at a high valuation with a price-to-earnings ratio of 122.17 and a negative return on equity of -576.45%, reflecting market concerns regarding its financial structure.
The biopharmaceutical giant also announced a quarterly dividend to be paid on August 14th for shareholders of record on July 15th. The payout amounts to $1.73 per share, representing an annualized yield of 2.8%. However, the company's dividend payout ratio is exceptionally high at 340.89%, indicating that the dividend is being funded from sources other than current earnings. AbbVie continues to focus on its portfolio in immunology, oncology, and neuroscience as it navigates these financial dynamics.
๐ Chicago Partners added 6,927 ABBV shares in Q1 for a total of 58,582.
๐ Worldquant Millennium grew its stake by 117.3% to $210.6 million in Q2.
๐ฐ AbbVie reported Q1 revenue of $15 billion, beating the $14.72 billion estimate.
โ ๏ธ Dividend payout ratio is dangerously high at 340.89%, exceeding current earnings.
๐ Stock trades at a premium P/E of 122.17 with negative return on equity.
๐ Chicago Partners Investment Group LLC increased its ABBV holdings by 13.4% in Q1, adding 6,927 shares to a total stake of 58,582 shares.
๐ Worldquant Millennium Advisors LLC significantly grew its position by 117.3% in Q2, purchasing an additional 612,702 shares valued at $210.6 million.
๐ Revolve Wealth Partners LLC boosted its stake by 72.7% in Q4, acquiring 3,064 shares worth $1.29 million.
๐ฐ AbbVie reported Q1 revenue of $15 billion, a 12.4% increase year-over-year that beat the consensus estimate of $14.72 billion.
๐ The company posted EPS of $2.65 for the quarter, surpassing analyst expectations of $2.59 by $0.06.
๐ธ AbbVie announced a quarterly dividend of $1.73 per share to be paid on August 14th with an ex-dividend date of July 15th.
โ ๏ธ The company's dividend payout ratio is extremely high at 340.89%, suggesting the dividend is not fully covered by current earnings.
๐ AbbVie trades at a premium valuation with a price-to-earnings ratio of 122.17 and a negative return on equity of -576.45%.
๐ข Institutional investors collectively own 70.23% of the company's outstanding stock, indicating strong institutional confidence.
๐ฌ AbbVie focuses its operations on complex medical conditions across immunology, oncology, neuroscience, virology, and women's health.
Bullish Signals
AbbVie beat estimates with $2.65 EPS versus $2.59 consensus.
Revenue grew 12.4% YoY to $15 billion, beating expectations.
Hedge funds like Worldquant and Chicago Partners increased stakes.
Company declared $1.73 per share dividend for upcoming quarter.
Risk Factors
Negative ROE of -576.45% signals capital structure challenges.
Sustainable dividend payout ratio is 340.89%, relying on other sources.
High P/E ratio of 122.17 suggests significant valuation risks.
Bullish Signals
AbbVie beat analyst earnings estimates with $2.65 EPS versus a consensus of $2.59, demonstrating operational strength.
Revenue grew by 12.4% year-over-year to reach $15 billion, exceeding the market expectation of $14.72 billion.
Multiple prominent hedge funds, including Worldquant Millennium Advisors and Chicago Partners, have increased their stakes in the stock.
The company maintains a consistent dividend policy with a declared payout of $1.73 per share for the upcoming quarter.
Risk Factors
AbbVie reports a negative return on equity of -576.45%, indicating significant leverage or capital structure challenges.
The dividend payout ratio stands at 340.89%, which is unsustainable based on current earnings and relies on other capital sources.
The stock trades at a very high price-to-earnings ratio of 122.17, suggesting the market prices in significant future growth or faces valuation risks.
Arbor Capital Management Inc. ADV established a new position in AbbVie Inc. (NYSE: ABBV) during the first quarter, purchasing 27,001 shares valued at approximately $5.63 million. This acquisition makes AbbVie the firm's largest holding, accounting for roughly 4.6% of its portfolio. Concurrently, several other major institutional investors have significantly increased their stakes in the biopharmaceutical giant. Norges Bank added a stake worth about $5.87 billion, while Wellington Management Group LLP lifted its holdings by 457.4% to own over 10.5 million shares valued at $2.44 billion.
Capital World Investors and Cardano Risk Management B.V. also substantially grew their positions in the fourth quarter, with the latter increasing its stake by 914.6%. Geode Capital Management LLC further increased its ownership to nearly 44.6 million shares, worth approximately $10.18 billion. Collectively, hedge funds and institutional investors now control 70.23% of the company's outstanding stock, indicating strong continued confidence from major capital allocators.
Fundamental performance remains robust as AbbVie recently reported quarterly earnings that beat analyst expectations. The company posted $2.65 per share in earnings against a consensus of $2.59, driven by revenue of $15 billion which exceeded the $14.72 billion forecast and represented a 12.4% year-over-year increase. Analysts project full-year earnings of $14.39 per share for the current fiscal year, suggesting sustained profitability despite high payout ratios.
The stock has received multiple upgrades from major research firms including Bank of America, DZ Bank, Canaccord Genuity Group, and Cantor Fitzgerald, with price targets ranging from $265 to $276. The company maintains a consistent dividend policy with an upcoming payment of $1.73 per share on August 14th for shareholders of record on July 15th, offering a yield of 2.8%. These developments collectively reinforce AbbVie's status as a core holding for institutional investors.
๐ Arbor Capital bought 27,001 AbbVie shares for $5.63 million.
๐ฆ Norges Bank added a new stake worth $5.87 billion.
๐ฐ Wellington Management increased holdings by 457.4% to $2.44 billion.
๐ต Q4 earnings beat estimates at $2.65 per share.
๐ผ Analysts maintain 'Moderate Buy' with average target of $262.81.
๐ Arbor Capital Management Inc. ADV bought 27,001 shares of AbbVie in Q1, valuing the new position at $5.63 million to make it its largest holding.
๐ฆ Norges Bank acquired a massive new stake worth approximately $5.87 billion in the fourth quarter.
๐ Wellington Management Group LLP increased its holdings by 457.4% to own over 10.5 million shares valued at $2.44 billion.
๐ฐ Capital World Investors lifted its position by 106.3% in Q4, now owning 13.07 million shares worth $2.99 billion.
๐ Cardano Risk Management B.V. grew its stake by 914.6% to own 5.44 million shares valued at $1.24 billion.
๐ Geode Capital Management LLC increased its position by 10.4%, holding 44.63 million shares worth $10.18 billion.
๐ Institutional ownership of AbbVie stands at 70.23% following these significant accumulation activities.
๐ต AbbVie reported Q4 earnings of $2.65 per share, beating the consensus estimate of $2.59 by $0.06.
๐ Revenue reached $15 billion for the quarter, surpassing analyst expectations of $14.72 billion and growing 12.4% year-over-year.
๐ฏ Analysts forecast full-year earnings of $14.39 per share for the current fiscal year.
๐ธ The company announced a quarterly dividend of $1.73 per share payable on August 14th with an ex-dividend date of July 15th.
๐ AbbVie reported a net margin of 5.79% and a negative return on equity of -576.45% for the quarter.
๐ผ Bank of America raised its price target to $276.00 and reaffirmed a 'buy' rating on the stock.
๐ผ DZ Bank upgraded AbbVie from a 'hold' to a 'strong-buy' rating in late April.
๐ผ Canaccord Genuity Group lifted its price objective to $273.00 and issued a 'buy' rating.
๐ผ Cantor Fitzgerald boosted its target price to $265.00 with an 'overweight' rating.
๐ The consensus analyst rating is currently 'Moderate Buy' with an average price target of $262.81.
๐ฅ AbbVie focuses on therapies for complex chronic conditions across immunology, oncology, neuroscience, virology, and women's health.
๐ The company was spun off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois.
Bullish Signals
Arbor Capital made AbbVie largest holding at 4.6%.
Norges Bank acquired $5.87 billion stake in Q4.
Wellington Management increased holdings by 457.4% to $2.44B.
Capital World Investors lifted position by 106.3% to $2.99B.
Institutional ownership stands at 70.23% after accumulation.
Q4 earnings of $2.65 beat estimate of $2.59.
Revenue reached $15 billion, up 12.4% year-over-year.
Analysts forecast full-year earnings of $14.39 per share.
Bank of America raised target to $276 with 'buy'.
DZ Bank upgraded to 'strong-buy' in late April.
Canaccord Genuity lifted target to $273 with 'buy'.
Bullish Signals
Arbor Capital Management Inc. ADV established a new position in AbbVie during Q1, making the stock its largest holding at 4.6% of portfolio value.
Norges Bank acquired a substantial new stake worth approximately $5.87 billion in the fourth quarter.
Wellington Management Group LLP increased its holdings by 457.4% to own over 10.5 million shares valued at $2.44 billion.
Capital World Investors lifted its position by 106.3% in Q4, now owning 13.07 million shares worth $2.99 billion.
Cardano Risk Management B.V. grew its position by 914.6% to own 5.44 million shares valued at $1.24 billion.
Geode Capital Management LLC increased its stake by 10.4%, holding 44.63 million shares worth $10.18 billion.
Institutional ownership of AbbVie stands at 70.23% following these significant accumulation activities.
AbbVie reported Q4 earnings of $2.65 per share, beating the consensus estimate of $2.59 by $0.06.
Revenue reached $15 billion for the quarter, surpassing analyst expectations of $14.72 billion and growing 12.4% year-over-year.
Analysts forecast full-year earnings of $14.39 per share for the current fiscal year.
Bank of America raised its price target to $276.00 and reaffirmed a 'buy' rating on the stock.
DZ Bank upgraded AbbVie from a 'hold' to a 'strong-buy' rating in late April.
Canaccord Genuity Group lifted its price objective to $273.00 and issued a 'buy' rating.
Cantor Fitzgerald boosted its target price to $265.00 with an 'overweight' rating.
The consensus analyst rating is currently 'Moderate Buy' with an average price target of $262.81.
Burney Co. reduced its position in AbbVie Inc. (NYSE: ABBV) by 28.6% during the first quarter, selling 17,320 shares and retaining a stake worth $9.42 million. While Burney decreased its holdings, several other institutional investors increased their positions in the fourth quarter, including Chelsea Counsel Co., Litman Gregory Wealth Management LLC, Imprint Wealth LLC, Westend Capital Management LLC, and IFC & Insurance Marketing Inc., with stakes ranging from approximately $26,000 to $31,000.
AbbVie stock is currently trading at $254.77, maintaining a market capitalization of $450.13 billion and a PE ratio of 125.50. The company recently announced a quarterly dividend of $1.73 per share payable on August 14th to shareholders of record on July 15th, resulting in an annualized dividend yield of 2.7% and a payout ratio of 340.89%. Analyst consensus remains moderately bullish with an average target price of $256.67.
Wall Street analysts have recently issued mixed but generally positive ratings on the stock. Piper Sandler reiterated an overweight rating with a $298.00 price objective, while Morgan Stanley and DZ Bank upgraded their targets or ratings to overweight and strong-buy respectively. The company maintains a diverse product portfolio across immunology, oncology, neuroscience, virology, and women's health, supported by 70.23% institutional ownership.
๐ Burney Co. sold 17,320 AbbVie shares, retaining a $9.42 million stake.
๐ฐ AbbVie pays a $1.73 quarterly dividend with a 2.7% yield.
๐ Stock trades at $254.77 with a market cap of $450.13 billion.
๐ฏ Analysts target $298.00 (Piper Sandler) and $278.00 (Morgan Stanley).
๐๏ธ Institutional investors own 70.23% of AbbVie's outstanding shares.
๐ Burney Co. reduced its AbbVie holdings by 28.6% in Q1, selling 17,320 shares while retaining a $9.42 million stake.
๐ Multiple other institutions including Chelsea Counsel Co., Litman Gregory Wealth Management LLC, and Imprint Wealth LLC added new or increased stakes in Q4.
๐ฐ AbbVie declared a quarterly dividend of $1.73 per share with an ex-dividend date of July 15th and a yield of 2.7%.
๐ The stock trades at $254.77 with a market cap of $450.13 billion and a PE ratio of 125.50.
๐ฏ Piper Sandler maintains an overweight rating with a price target of $298.00, while Morgan Stanley raised its target to $278.00.
๐ฅ AbbVie operates across five major therapeutic areas including immunology, oncology, neuroscience, virology, and women's health.
๐ The stock has a 50-day moving average of $221.27 and a 200-day moving average of $220.47.
๐๏ธ Institutional investors own 70.23% of the company's outstanding shares.
Bullish Signals
Multiple institutional investors increased or initiated positions in Q4.
Piper Sandler targets $298.00, well above current price.
Morgan Stanley and DZ Bank raised target prices to $278.00.
Company offers 2.7% dividend yield with 340.89% payout ratio.
Institutional ownership stands at 70.23%.
Risk Factors
Position reduced by 28.6% selling 17,320 shares.
Downgraded from strong-buy to buy rating.
Payout ratio of 340.89% exceeds 100%.
Bullish Signals
Multiple institutional investors including Chelsea Counsel Co., Litman Gregory Wealth Management LLC, Imprint Wealth LLC, Westend Capital Management LLC, and IFC & Insurance Marketing Inc. increased or initiated positions in Q4.
Piper Sandler reiterated an overweight rating with a price objective of $298.00, significantly above the current trading price.
Morgan Stanley upgraded its target price to $278.00 and DZ Bank upgraded its rating to strong-buy.
The company maintains a high dividend yield of 2.7% with a payout ratio of 340.89%, indicating a commitment to shareholder returns.
Institutional ownership stands at 70.23%, suggesting continued confidence from large capital managers.
Risk Factors
Burney Co. significantly reduced its position by 28.6% in the first quarter, selling 17,320 shares.
Wall Street Zen downgraded the stock from a strong-buy rating to a buy rating.
The payout ratio of 340.89% exceeds 100%, indicating dividends are being paid from capital or reserves rather than current earnings.
AbbVie Inc. (NYSE: ABBV) reported Q1 2023 revenue of $12.23 billion, a ~10% year-over-year decline, and adjusted EPS of $2.46, down 22%, primarily due to the anticipated impact of Humira's patent expiration. Despite this earnings contraction, the company maintained resilient performance with strong cash generation, paying $10.5 billion in dividends during 2023 and raising its quarterly dividend by 4.7% to $1.55 per share effective February 2024.
The article details AbbVie's substantial debt load of $59.4 billion as of year-end 2023, largely stemming from the 2020 Allergan acquisition, though the company has proactively deleveraged by repaying over $4 billion in net debt in 2023. With a cash balance of $12.8 billion and operating cash flow of $22.8 billion in 2023, AbbVie comfortably covers its capital expenditures and dividend obligations, supported by credit upgrades to A- (S&P) and A3 (Moody's).
Key risks include the significant decline in Humira sales, which dropped 32% globally in 2023, and the challenge of replacing its ~$20 billion annual revenue peak with newer immunology drugs like Skyrizi ($7.8 billion) and Rinvoq ($4.0 billion). The company also faces regulatory headwinds such as Medicare price negotiations for Imbruvica starting in 2026, potential safety warnings for JAK inhibitors, and large contingent payment liabilities related to past acquisitions.
๐ฐ Dividend raised 4.7% to $1.55, yielding ~3%โ3.5%, above industry median.
๐ฆ Total debt is $59.4B with $7.2B due in 2024 and $8.8B in 2025.
๐ต Operating cash flow of $22.8B covers dividends 2.2x for AbbVie.
๐ Skyrizi ($7.8B) and Rinvoq ($4.0B) sales offset Humira's decline.
๐ Q1 2023 revenue fell ~10% YoY to $12.23 billion and adjusted EPS dropped 22% to $2.46 due to Humira's patent expiration.
๐ฐ AbbVie raised its quarterly dividend by 4.7% to $1.55, bringing the total annualized yield to approximately 3%โ3.5%, above the industry median.
๐ฆ Total debt stands at $59.4 billion as of year-end 2023, with significant maturities of ~$7.2 billion due in 2024 and ~$8.8 billion in 2025.
๐ต Operating cash flow reached $22.8 billion in 2023, providing roughly 2.2x coverage for the $10.5 billion in dividends paid.
๐ New immunology drugs Skyrizi and Rinvoq grew rapidly in 2023 with sales of $7.8 billion and $4.0 billion respectively, offsetting Humira's decline.
โ ๏ธ Global Humira revenue dropped 32% in 2023, creating a major near-term earnings headwind as the company transitions its portfolio.
๐ Oncology drug Imbruvica revenues fell 21% in 2023 due to competition, resulting in a $3.6 billion impairment charge.
โ๏ธ Credit rating agencies upgraded AbbVie to A- (S&P) and A3 (Moody's), reflecting confidence in its deleveraging progress.
๐ Forward P/E ratio is estimated at 15โ17x, which is reasonable for a large pharma peer despite elevated trailing multiples.
๐๏ธ U.S. Medicare price negotiations will target Imbruvica by 2026, potentially eroding revenue from this key franchise.
๐ธ AbbVie holds $12.8 billion in cash and has been actively reducing debt, paying down over $4 billion net in 2023.
๐ Contingent payment liabilities related to acquisitions increased by $5.1 billion in 2023 due to higher Skyrizi sales.
Bullish Signals
Dividend raised 4.7% to $1.55 with ~3%โ3.5% yield.
Generated $22.8B operating cash flow in 2023.
Skyrizi and Rinvoq sales grew 51% and 58%.
Credit ratings upgraded to A- (S&P) and A3 (Moody's).
Reduced debt by over $4 billion net in 2023.
Risk Factors
Q1 2023 revenue declined ~10% YoY to $12.23 billion.
Adjusted EPS fell 22% to $2.46 due to Humira loss.
Global Humira revenue dropped 32% in 2023 with U.S. sales down 35%.
Imbruvica revenues fell 21% leading to a $3.6 billion impairment charge.
Contingent liabilities reached nearly $20 billion, up $5.1 billion in 2023.
Bullish Signals
AbbVie raised its quarterly dividend by 4.7% to $1.55, resulting in a total annualized yield of approximately 3%โ3.5%, which exceeds the pharmaceutical industry median.
The company generated $22.8 billion in operating cash flow in 2023, comfortably covering its $10.5 billion dividend payments and capital expenditures with free cash flow coverage of roughly 2.2x.
New immunology products Skyrizi and Rinvoq demonstrated strong growth in 2023 with sales increases of 51% and 58% respectively, reaching combined sales of nearly $12 billion.
Credit rating agencies upgraded AbbVie to A- (S&P) and A3 (Moody's), signaling confidence in the company's ability to manage its debt load and cash flow outlook.
AbbVie has successfully deleveraged its balance sheet, reducing total debt by over $4 billion net in 2023 while maintaining a robust cash balance of $12.8 billion.
Risk Factors
Q1 2023 revenue declined ~10% year-over-year to $12.23 billion, and adjusted EPS fell 22% to $2.46, driven by the loss of exclusivity on Humira.
Global Humira revenue dropped 32% in 2023, with U.S. sales falling 35%, creating a significant near-term earnings headwind as the company transitions its portfolio.
Oncology franchise Imbruvica saw revenues fall 21% in 2023 due to competition, leading to a $3.6 billion impairment charge related to underperforming assets.
AbbVie faces large contingent payment liabilities of nearly $20 billion at fair value, which increased by $5.1 billion in 2023 due to higher Skyrizi sales.
Adams Diversified Equity Fund Inc. reduced its position in AbbVie Inc. by 31.1% in the first quarter, selling 58,300 shares to hold a remaining stake of 129,400 shares valued at $28.1 million. While this major fund decreased its exposure, several smaller institutional investors including Chelsea Counsel Co., Litman Gregory Wealth Management LLC, and Imprint Wealth LLC initiated or significantly increased their positions in the fourth quarter.
AbbVie reported strong quarterly financial results released on April 29th, with revenue reaching $15 billion, a 12.4% year-over-year increase that beat analyst expectations of $14.72 billion. The company posted earnings per share of $2.65, surpassing the consensus estimate of $2.59, and maintains a quarterly dividend of $1.73 payable on August 14th to shareholders of record by July 15th.
Analyst sentiment remains largely positive with recent upgrades from Piper Sandler and Canaccord Genuity, alongside reaffirmations from Guggenheim and Cantor Fitzgerald. The consensus price target stands at $253.81 based on ratings from multiple firms, reflecting confidence in the company's performance despite a high payout ratio of 340.89%.
๐ Adams Diversified Equity Fund sold 58,300 AbbVie shares, reducing stake by 31.1%.
๐ฐ AbbVie Q1 revenue hit $15 billion, beating analyst expectations of $14.72 billion.
๐ EPS reached $2.65, surpassing the consensus estimate of $2.59 by $0.06.
๐ต Quarterly dividend declared at $1.73 with an annualized yield of 2.8%.
๐ผ Analysts Piper Sandler and Canaccord Genuity raised price targets to $298 and $273.
๐ Adams Diversified Equity Fund Inc. sold 58,300 shares of AbbVie, reducing its position by 31.1% to hold 129,400 shares worth $28.1 million.
๐ Other institutional investors including Imprint Wealth LLC and Westend Capital Management LLC initiated or boosted their stakes in the fourth quarter.
๐ฐ AbbVie reported Q1 revenue of $15 billion, a 12.4% increase year-over-year that exceeded analyst expectations of $14.72 billion.
๐ The company posted earnings per share of $2.65, beating the consensus estimate of $2.59 by $0.06.
๐ต AbbVie declared a quarterly dividend of $1.73 with an ex-dividend date of July 15th and an annualized yield of 2.8%.
๐ Piper Sandler reissued an 'overweight' rating with a $298.00 price target on AbbVie shares.
๐ผ Canaccord Genuity raised its price target from $265.00 to $273.00 and maintained a 'buy' rating.
๐ The stock carries a high payout ratio of 340.89% based on the declared dividend amount.
๐ฅ AbbVie's revenue growth was driven by its portfolio in immunology, oncology, neuroscience, virology, and women's health.
๐ MarketBeat data shows a consensus price target of $253.81 with an average rating of 'Moderate Buy'.
Bullish Signals
Revenue hit $15B, up 12.4% year-over-year.
EPS reached $2.65, beating estimates by $0.06.
Piper Sandler set price target at $298.
Canaccord raised target to $273 with buy rating.
Guggenheim maintains buy rating at $249 target.
Cantor Fitzgerald reiterated overweight rating on shares.
Dividend yield stands at 2.8% annually.
Risk Factors
High payout ratio of 340.89% exceeds earnings per share.
Negative return on equity of -576.45% for the quarter.
Institutional holder reduced position by 31.1% in Q1.
Bullish Signals
AbbVie reported revenue of $15 billion, representing a 12.4% year-over-year increase that surpassed analyst expectations of $14.72 billion.
The company posted earnings per share of $2.65, beating the consensus estimate of $2.59 by $0.06.
Piper Sandler reissued an 'overweight' rating and set a price target of $298.00 on AbbVie shares.
Canaccord Genuity raised its price target from $265.00 to $273.00 and reaffirmed a 'buy' rating.
Guggenheim reaffirmed a 'buy' rating with a price target of $249.00 on AbbVie stock.
Cantor Fitzgerald reiterated an 'overweight' rating on AbbVie shares in its latest research report.
AbbVie maintains a quarterly dividend of $1.73, providing an annualized yield of 2.8% to investors.
Risk Factors
AbbVie has a high payout ratio of 340.89%, indicating that the declared dividend exceeds current earnings per share.
The company reported a negative return on equity of -576.45% for the quarter.
Adams Diversified Equity Fund Inc., a significant institutional holder, reduced its position by 31.1% in the first quarter.
Apella Capital LLC significantly increased its stake in AbbVie Inc. (NYSE: ABBV) by 97.9% in the first quarter, purchasing an additional 10,041 shares to hold a total of 20,298 shares valued at $4.23 million. Several other institutional investors, including Thoma Capital Management LLC and Consilium Wealth Advisory LLC, also boosted their positions during the same period, while Focused Wealth Management Inc. and Centennial Wealth Advisory LLC increased holdings by 9.3% and 6.5% respectively.
AbbVie reported strong quarterly financial results ending April 29th, with revenue of $15 billion that beat analyst estimates of $14.72 billion. The company achieved an earnings per share (EPS) of $2.65, surpassing the consensus estimate of $2.59, representing a year-over-year revenue increase of 12.4%. Analysts currently project an average EPS of $14.29 for the current fiscal year.
The company recently announced a quarterly dividend of $1.73 per share, payable on August 14th to stockholders of record as of July 15th, resulting in a 2.8% dividend yield. Major financial institutions have upgraded their ratings on AbbVie shares, including DZ Bank moving to a 'strong-buy' and Bank of America upgrading to a 'buy' with a $234 price objective, alongside Morgan Stanley raising its target price to $278.
๐ Apella Capital increased AbbVie stake by 97.9% to 20,298 shares.
๐ AbbVie Q1 revenue hit $15B, beating estimates with $2.65 EPS.
๐ฐ Quarterly dividend of $1.73 offers a 2.8% annualized yield.
๐ DZ Bank upgraded to 'strong-buy' and BofA to 'buy'.
๐ Morgan Stanley raised target price to $278 with 'overweight' rating.
๐ Apella Capital LLC increased its AbbVie stake by 97.9% in Q1, adding 10,041 shares for a total holding of 20,298 shares valued at $4.23 million.
๐ AbbVie reported Q1 revenue of $15 billion, beating estimates of $14.72 billion, with EPS of $2.65 versus an expected $2.59.
๐ Revenue grew 12.4% year-over-year, and analysts maintain a consensus price target of $253.81 for the stock.
๐ฐ The company declared a quarterly dividend of $1.73 per share with an annualized yield of 2.8% payable on August 14th.
๐ DZ Bank upgraded AbbVie to 'strong-buy' and Bank of America upgraded it to 'buy' with a $234 price objective.
๐ Morgan Stanley raised its target price from $270.00 to $278.00 while reaffirming an 'overweight' rating.
๐๏ธ Institutional ownership stands at 70.23%, with multiple wealth management firms increasing their positions in Q1.
Bullish Signals
AbbVie beat earnings with $2.65 EPS vs $2.59 consensus.
Revenue hit $15 billion, beating the $14.72B estimate.
Revenue grew 12.4% year-over-year.
DZ Bank upgraded stock to 'strong-buy'.
Bank of America set $234 price target.
Bullish Signals
AbbVie beat quarterly earnings estimates with $2.65 EPS compared to the consensus of $2.59.
Revenue reached $15 billion, exceeding analyst expectations of $14.72 billion.
The company achieved a 12.4% year-over-year revenue increase.
DZ Bank upgraded the stock rating from 'hold' to 'strong-buy'.
Bank of America upgraded the rating to 'buy' and set a $234 price objective.
Morgan Stanley increased its target price to $278.00.
Apella Capital LLC significantly boosted its position by 97.9% in Q1.
Multiple institutional investors including Thoma Capital and Consilium Wealth Advisory increased their stakes.
AbbVie (NYSE: ABBV) recently presented landmark nine-year follow-up data from the Phase 3 CLL14 trial at the European Hematology Association 2026 meeting. The results confirm that a one-year fixed-duration venetoclax combination therapy provides a median of approximately eight years off treatment before requiring further intervention. AbbVie's oncology leadership highlighted these findings as affirming the drug's enduring safety and efficacy, offering patients unprecedented time to their next treatment in first-line chronic lymphocytic leukemia.
This clinical breakthrough reinforces AbbVie's post-Humira pipeline narrative, demonstrating its ability to innovate beyond its legacy immunology blockbusters. The company is strategically navigating the loss of exclusivity on Humira by leaning on new therapies like venetoclax, Skyrizi, and Rinvoq to drive future growth. Concurrently, AbbVie has increased its quarterly dividend to $1.64 per share starting February 2025, extending a multi-year streak of steady dividend growth despite the transition period.
Financially, AbbVie generated $18.8 billion in operating cash flow in 2024, funding $11.0 billion in dividends while leaving over $7 billion in free cash flow. The company has actively deleveraged its balance sheet, paying down $9.6 billion of debt in 2024 and receiving a credit rating upgrade from Moody's to A2 Stable. While the stock trades at a premium valuation with a GAAP P/E over 100 due to non-cash charges, it offers a forward P/E of roughly 15โ17x and a dividend yield near 2.8%.
๐ Venetoclax offers ~8 years off-treatment in first-line CLL per nine-year trial data.
๐ฐ Board approved a 5.8% dividend hike to $1.64/share starting February 2025.
๐ต AbbVie generated $18.8B operating cash flow in 2024 with $7B+ free cash flow.
๐ Total long-term debt was ~$67B at year-end 2024 after paying down $9.6B.
๐ AbbVie unveiled nine-year follow-up data from the CLL14 trial showing venetoclax provides a median of ~8 years off treatment in first-line chronic lymphocytic leukemia.
๐ฐ The board approved a ~5.8% quarterly dividend hike to $1.64 per share starting February 2025, maintaining a streak of annual increases since the 2013 spin-off.
๐ต AbbVie generated $18.8 billion in operating cash flow in 2024, funding $11.0 billion in dividends and leaving over $7 billion in free cash flow.
๐ Total long-term debt stood at about $67 billion as of year-end 2024, with the company paying down a net $9.6 billion in 2024 to reduce leverage.
๐ Moody's upgraded AbbVie's credit rating to A2 Stable in early 2026, citing improving post-Humira performance and strong free cash flow generation.
๐ Shares rallied approximately 25% over the past year as of early 2026, driven by optimism in new immunology and oncology products.
โ ๏ธ Humira U.S. patent expired in January 2023, causing sales to plunge 41% in 2024 as the company transitions to newer therapies.
๐ฌ Skyrizi revenue jumped ~76% in 2022 with continued double-digit growth through 2024, helping offset declines in legacy immunology drugs.
โ๏ธ AbbVie carries over $70 billion in goodwill and intangible assets, taking a $3.5 billion impairment charge on certain assets in 2024.
๐ U.S. Medicare negotiations under the Inflation Reduction Act have targeted AbbVie's Imbruvica for future price controls.
Bullish Signals
CLL14 trial confirms ~8 years off treatment for venetoclax.
Dividend increased ~5.8% to $1.64/share starting Feb 2025.
Generated $18.8B operating cash flow in 2024.
Moody's upgraded credit rating to A2 Stable.
Paid down net $9.6B debt in 2024.
Shares returned ~25% over past year.
Skyrizi revenue jumped ~76% in 2022.
Risk Factors
GAAP P/E exceeds 100 due to heavy non-cash amortization charges.
$67 billion debt load limits flexibility for future acquisitions or R&D.
$3.5 billion impairment charge on intangible assets in 2024.
Humira, Skyrizi, and Rinvoq account for ~47% of total revenue.
Bullish Signals
Landmark nine-year data from the CLL14 trial confirms venetoclax offers a median of ~8 years off treatment, affirming its safety and efficacy in first-line chronic lymphocytic leukemia.
AbbVie increased its quarterly dividend by ~5.8% to $1.64 per share starting February 2025, extending a multi-year streak of consistent dividend growth.
The company generated $18.8 billion in operating cash flow in 2024, easily funding dividends and leaving over $7 billion in free cash flow for debt reduction or investments.
Moody's upgraded AbbVie's credit rating to A2 Stable with a stable outlook, reflecting improving post-Humira performance and robust annual free cash flow exceeding $10 billion after dividends.
AbbVie paid down a net $9.6 billion of debt in 2024 while maintaining investment-grade ratings (S&P affirmed Aโ), demonstrating active balance sheet management.
Shares returned about 25% over the past year as of early 2026, reflecting strong market confidence in the company's new immunology and oncology product pipeline.
Skyrizi revenue grew rapidly with a ~76% jump in 2022 and sustained double-digit growth through 2024, signaling successful replacement of legacy drug sales.
Risk Factors
AbbVie's GAAP P/E ratio exceeds 100 due to heavy non-cash amortization charges, making the stock appear richly valued on trailing earnings despite a more reasonable forward multiple.
The company carries a significant debt load of approximately $67 billion as of year-end 2024, which limits flexibility for future acquisitions or major R&D spending spikes.
AbbVie took a $3.5 billion impairment charge on certain intangible assets in 2024, reflecting disappointments in parts of its acquired portfolio and signaling potential underperformance.
Humira, Skyrizi, and Rinvoq together accounted for ~47% of total revenue in 2024, creating high product concentration risk if new drugs fail to fully replace Humira's peak sales.
AbbVie (ABBV) has successfully transitioned from its Humira patent cliff by scaling its Skyrizi and Rinvoq immunology franchises, driving a 28% stock gain over the past year. The company recently announced an all-cash acquisition of clinical-stage biotech Apogee Therapeutics for nearly $11 billion to bolster its long-term pipeline into the 2030s, a move that caused shares to surge another 6.25% despite the significant cash outlay.
Financially, AbbVie demonstrated resilience in its most recent quarter with total revenue growing 12.4% to $15.0 billion even as legacy Humira sales cratered by over 40%. Skyrizi sales jumped 29.2% to $4.5 billion and Rinvoq climbed 20.2% to $2.1 billion, effectively replacing lost revenue. However, the company trades at a premium valuation with a forward P/E of 16x compared to a four-year average of 13x, reflecting high market expectations for sustained growth.
The balance sheet remains strong with operating cash flow converting 33.8% of revenue to generate roughly $21.2 billion annually, allowing the company to fund acquisitions without dilution or excessive debt. Despite elite operating margins of 33.2%, net margins are lower at 5.8% due to significant R&D write-offs from recent deals like ImmunoGen and Cerevel. Investors must weigh this aggressive growth strategy against clinical execution risks in the Apogee deal and potential volatility in a crowded immunology market.
๐ Stock rose 6.25% on $11B Apogee acquisition.
๐ฐ Revenue grew 12.4% to $15.0B despite Humira drop.
๐ AbbVie stock rose 6.25% following the announcement of a nearly $11 billion all-cash acquisition of Apogee Therapeutics to strengthen its immunology pipeline.
๐ฐ Total company revenue grew 12.4% year-over-year to $15.0 billion in the most recent quarter despite a 40.3% decline in legacy Humira sales.
๐ฌ Skyrizi sales surged 29.2% to $4.5 billion while Rinvoq global sales climbed 20.2% to $2.1 billion, successfully replacing blockbuster revenue.
๐ต The company generated approximately $21.2 billion in operating cash flow over the last year, converting 33.8% of its total revenue into cash.
๐ AbbVie trades at a forward price-to-earnings ratio of 16x, which is higher than its four-year average of 13x and significantly above the market's 3.2x P/S ratio.
โ๏ธ Operating margins remain elite at 33.2%, substantially outperforming the broader market average of 18.4%.
๐ฆ Debt levels are manageable at 19.0% of market capitalization, sitting below the broader market average of 21.3%.
โ ๏ธ Oncology segment revenues slipped by 3% and Juvederm aesthetic filler sales fell 2.9% amid macroeconomic headwinds.
๐ Net margins sit at 5.8% versus the S&P 500's 13.0%, primarily due to $12.7 billion in pre-tax acquired IPR&D and milestone write-offs.
๐ฏ The Apogee acquisition carries binary clinical execution risk, specifically regarding the safety profile of Zumilokibart in Phase 3 trials.
๐ High Beta Risk: The stock fell 23% during the 2022 inflation shock and 34% during the 2020 pandemic crash, matching broader market declines.
๐ Options market implied volatility stands at 27, placing it in the 74th percentile and indicating traders expect larger-than-average price swings.
Bullish Signals
Total revenue grew 12.4% despite a 40.3% Humira sales drop.
Skyrizi sales surged 29.2% to $4.5 billion.
Rinvoq global sales climbed 20.2% to $2.1 billion.
Neuroscience revenues jumped 24.3% to nearly $2.9 billion.
Elite operating margin of 33.2% outperforms market average of 18.4%.
Converts 33.8% of revenue into operating cash flow.
Absorbed $11 billion Apogee acquisition without debt or dilution.
Stock rallied 6.25% after Apogee deal announcement.
Risk Factors
Forward P/E of 16x exceeds four-year average of 13x.
On oncology revenues slipped 3% amid key therapeutic weakness.
Juvederm sales fell 2.9% due to macroeconomic headwinds.
Net margins compressed to 5.8% versus S&P 500's 13.0%.
$12.7 billion pre-tax write-offs from ImmunoGen and Cerevel deals.
Bullish Signals
AbbVie successfully navigated its historic patent cliff, replacing Humira revenue with aggressive growth from Skyrizi and Rinvoq.
The company demonstrated operational detachment from past anchors by growing total revenue 12.4% despite a 40.3% drop in Humira sales.
Skyrizi sales surged 29.2% to $4.5 billion, establishing itself as a dominant new franchise in the immunology space.
Rinvoq global sales climbed 20.2% to $2.1 billion, further diversifying the company's high-growth portfolio.
Neuroscience revenues jumped 24.3% to nearly $2.9 billion, showing strength in a second major growth segment.
The company possesses an elite operating margin of 33.2%, significantly outperforming the broader market average of 18.4%.
AbbVie is a powerful cash-generation machine, converting 33.8% of revenue into operating cash flow to fund acquisitions and R&D.
The balance sheet is pristine with ample liquidity to absorb the $11 billion Apogee acquisition without diluting shareholders or taking on burdensome debt.
The stock rallied 6.25% immediately after the Apogee deal announcement, signaling strong investor confidence in the strategic value of the acquisition.
Risk Factors
AbbVie trades at a significant premium with a forward P/E of 16x versus its four-year average of 13x, leaving little room for error.
The oncology segment saw revenues slip by 3%, indicating weakness in a key therapeutic area.
Sales of Juvederm aesthetic fillers fell 2.9% amid lingering macroeconomic headwinds, adding to revenue pressure.
Net margins are compressed at 5.8% compared to the S&P 500's 13.0% due to aggressive M&A activity and associated write-offs.
The company recorded $12.7 billion in pre-tax acquired IPR&D and milestone write-offs over the trailing twelve months from deals like ImmunoGen and Cerevel.
Elevated Volatility: Options market implied volatility is at 27 (74th percentile), suggesting traders brace for larger-than-average price swings.
Clinical Execution Risk: The $11 billion Apogee deal carries binary risk; if Zumilokibart encounters safety issues or fails Phase 3 trials, the high valuation could face a sharp reset.
BI Asset Management Fondsmaeglerselskab A S significantly increased its stake in AbbVie Inc. (NYSE:ABBV) by 57.0% during the first quarter, purchasing an additional 163,535 shares to hold a total of 450,556 shares valued at $97.8 million. This position represents approximately 1.0% of the firm's portfolio and ranks as its 18th largest holding. Several other institutional investors, including Chelsea Counsel Co., Litman Gregory Wealth Management LLC, Westend Capital Management LLC, Imprint Wealth LLC, and Texas Capital Bancshares Inc TX, also established or increased their positions in the stock during the third and fourth quarters.
AbbVie shares opened at $216.63 with a market capitalization of $382.74 billion. The company recently announced a quarterly dividend of $1.73 per share, payable on August 14th to shareholders of record as of July 15th. This dividend represents an annualized yield of 3.2% and a payout ratio of 340.89%. Technical indicators show the stock trading above its 50-day moving average but below its 200-day moving average, with a PEG ratio of 0.66.
Analyst sentiment remains positive with multiple firms maintaining or upgrading their ratings on AbbVie. William Blair and BMO Capital Markets reiterated 'outperform' ratings, while Canaccord Genuity raised its price objective to $265.00 with a 'buy' rating. DZ Bank upgraded the stock to 'strong-buy,' contributing to a consensus 'Moderate Buy' rating from MarketBeat with an average target price of $253.43. The company continues to focus on therapies for complex medical conditions across immunology, oncology, neuroscience, virology, and women's health.
๐ BI Asset Management increased AbbVie stake by 57% to 450,556 shares.
๐ฐ New position valued at $97.8 million representing 1.0% of portfolio assets.
๐ฏ Analysts bullish with Canaccord Genuity raising target to $265.00.
๐ต Quarterly dividend declared at $1.73 per share ex-date July 15th.
๐ Stock trades at $382.74B market cap with PEG ratio of 0.66.
๐ BI Asset Management increased its AbbVie stake by 57.0% in Q1, adding 163,535 shares to a total holding of 450,556 shares.
๐ฐ The firm's new position is valued at $97.8 million and represents 1.0% of its total portfolio assets.
๐ Other institutions including Chelsea Counsel Co., Litman Gregory Wealth Management, and Texas Capital Bancshares initiated new positions in Q3 or Q4.
๐ต AbbVie declared a quarterly dividend of $1.73 per share with an ex-dividend date of July 15th.
๐ The stock trades at a market cap of $382.74 billion with a PEG ratio of 0.66 and a beta of 0.32.
๐ฏ Analysts maintain bullish sentiment, with Canaccord Genuity raising its price target to $265.00 and DZ Bank upgrading to 'strong-buy'.
๐ MarketBeat consensus rating is 'Moderate Buy' with an average 12-month price target of $253.43.
๐ฅ AbbVie operates in immunology, oncology, neuroscience, virology, and women's health therapeutic areas.
๐ The company has a 52-week trading range between $181.73 and $244.81.
Bullish Signals
BI Asset Management increased holdings by 57.0% in Q1.
Multiple new institutional buyers entered positions in Q3 and Q4.
Analyst consensus is Moderate Buy with $253.43 price target.
Canaccord Genuity raised objective to $265.00 on buy rating.
DZ Bank upgraded stock from hold to strong-buy.
Bullish Signals
Major institutional investor BI Asset Management increased its holdings by 57.0% in Q1, signaling continued confidence in the stock.
Multiple new institutional buyers entered positions in Q3 and Q4, including Chelsea Counsel Co., Litman Gregory Wealth Management, Westend Capital Management, Imprint Wealth, and Texas Capital Bancshares.
Analyst consensus is positive with a 'Moderate Buy' rating and an average price target of $253.43, which is above the recent trading price.
Canaccord Genuity increased its price objective to $265.00 and maintained a 'buy' rating on the stock.
DZ Bank upgraded AbbVie from 'hold' to 'strong-buy', adding to the bullish analyst sentiment.
William Blair and BMO Capital Markets reiterated their 'outperform' ratings, indicating sustained institutional support.
AbbVie announced on Monday a definitive agreement to acquire Apogee Therapeutics for $10.9 billion, marking the company's largest buyout in over five years. The deal is strategically designed to strengthen AbbVie's immunology portfolio, specifically targeting inflammatory diseases such as atopic dermatitis and asthma, as it navigates patent expirations on its key assets.
The acquisition provides immediate access to Apogee's lead candidate, zumilokibart, an experimental therapy intended for subcutaneous injection every three or six months. This dosing frequency offers a potential convenience advantage over Sanofi and Regeneron's blockbuster Dupixent, which requires bi-weekly administration. AbbVie CEO Robert Michael characterized the deal as an excellent strategic fit with the potential to achieve 'mega-blockbuster' status.
AbbVie plans to fund the transaction through debt, offering $135.11 per Apogee share, a 49.49% premium to the stock's recent close. The company expects the deal to close in the third quarter and contribute to adjusted earnings per share by 2032. AbbVie's immunology franchise generated over $30 billion in revenue in 2025, driven by growth in Skyrizi and Rinvoq despite a significant decline in Humira sales.
Analysts from J.P. Morgan and RBC Capital Markets view the acquisition positively, noting that investors have been seeking late-stage growth assets to counter declining demand for former top sellers. The deal underscores a broader trend of pharmaceutical companies racing to build robust pipelines ahead of looming patent cliffs on blockbuster treatments.
๐ AbbVie acquires Apogee Therapeutics for $10.9 billion.
๐ Deal includes zumilokibart with 3-6 month dosing.
๐ Immunology franchise revenue hit $30 billion in 2025.
๐ฐ Offer price is $135.11 per share (49.49% premium).
๐ Transaction expected to close in the third quarter.
๐ AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion, its largest buyout in more than five years.
๐ The deal grants access to zumilokibart, an experimental treatment for inflammatory diseases with a dosing frequency of once every three or six months.
๐ AbbVie's immunology franchise generated over $30 billion in revenue in 2025, up 14% from the previous year.
๐ฐ The acquisition is funded through debt at an offer price of $135.11 per Apogee share, representing a 49.49% premium.
๐ The transaction is expected to close in the third quarter and add to adjusted earnings per share by 2032.
๐ฌ Zumilokibart offers a potential convenience advantage over Dupixent due to less frequent subcutaneous injections.
๐ AbbVie shares rose 4.6% following the announcement of the acquisition deal.
๐ Apogee shares surged 50% in early trading after the agreement was announced.
๐ CEO Robert Michael described the deal as an excellent fit with potential for 'mega-blockbuster' peak sales.
๐ Analysts from J.P. Morgan and RBC Capital Markets believe the deal makes sense for maximizing zumilokibart's potential.
Bullish Signals
AbbVie acquires Apogee for $10.9B, largest buyout in five years.
Zumilokibart dosing every 3-6 months beats Dupixent convenience.
Immunology franchise generated over $30B revenue in 2025.
Analysts view deal as well-received growth asset move.
Shares rose 4.6% on positive market sentiment.
Bullish Signals
AbbVie is acquiring Apogee Therapeutics for $10.9 billion, its largest buyout in over five years, signaling strong strategic confidence.
The lead candidate zumilokibart offers a potentially more convenient dosing schedule (every 3-6 months) compared to competitors like Dupixent.
AbbVie's immunology franchise generated over $30 billion in revenue in 2025, demonstrating robust growth despite Humira declines.
Analysts from J.P. Morgan and RBC Capital Markets view the deal as a well-received move for investors seeking late-stage growth assets.
The acquisition is expected to close in Q3 and contribute to adjusted earnings per share by 2032, indicating long-term value creation.
AbbVie shares rose 4.6% immediately following the announcement, reflecting positive market sentiment toward the deal.
Risk Factors
The $10.9 billion acquisition will be funded through debt, increasing AbbVie's leverage and interest obligations.
Claris Financial LLC increased its investment in AbbVie Inc. (NYSE: ABBV) during the fourth quarter by purchasing 7,840 shares valued at approximately $1.79 million. This acquisition represents about 1% of Claris's portfolio, making it the firm's 18th largest holding. Several other institutional investors also adjusted their positions recently, including Chelsea Counsel Co., Litman Gregory Wealth Management LLC, Westend Capital Management LLC, and Texas Capital Bancshares Inc., which all established new stakes ranging from $26,000 to $31,000.
AbbVie reported strong quarterly financial results announced on April 29th, with revenue reaching $15 billion, a 12.4% year-over-year increase that surpassed analyst estimates of $14.72 billion. The company posted earnings per share of $2.65, beating the consensus estimate of $2.59 by $0.06. Analysts currently project full-year EPS of 14.3 for the current fiscal year. The stock recently opened at $216.63, trading above its 50-day moving average but below its 200-day moving average.
The company has announced a quarterly dividend to be paid on August 14th for shareholders of record as of July 15th. The dividend amount is set at $1.73 per share, which annualizes to $6.92 and yields 3.2%. AbbVie, spun off from Abbott Laboratories in 2013, focuses on therapies for complex medical conditions across immunology, oncology, neuroscience, virology, and women's health sectors.
๐ Claris Financial bought 7,840 shares worth $1.79 million in Q4.
๐ Other investors opened new positions ranging from $26k to $31k.
๐ฐ Revenue hit $15 billion, a 12.4% increase beating estimates.
๐ EPS reached $2.65, topping the consensus by $0.06.
๐ต Quarterly dividend of $1.73 per share set for August 14th.
๐ Claris Financial LLC purchased a new stake of 7,840 shares in AbbVie valued at approximately $1.79 million during the fourth quarter.
๐ Several other institutional investors including Chelsea Counsel Co., Litman Gregory Wealth Management LLC, and Westend Capital Management LLC established new positions ranging from $26,000 to $31,000.
๐ฐ AbbVie reported quarterly revenue of $15 billion, representing a 12.4% year-over-year increase that beat analyst estimates.
๐ The company posted earnings per share of $2.65, topping the consensus estimate of $2.59 by $0.06.
๐ต AbbVie announced a quarterly dividend of $1.73 per share to be paid on August 14th with an ex-dividend date of July 15th.
๐ The stock currently trades at a PE ratio of 106.71 and has a market capitalization of $382.74 billion.
๐ฌ AbbVie's product portfolio covers major therapeutic categories including immunology, oncology, neuroscience, virology, and women's health.
Bullish Signals
Revenue hit $15B, up 12.4% year-over-year.
EPS of $2.65 beat the $2.59 consensus.
Institutional ownership stands at 70.23%.
Dividend yield reaches 3.2%.
Revenue exceeded expectations of $14.72B.
Risk Factors
Stock trades below 200-day moving average of $218.78.
Payout ratio of 340.89% indicates dividend paid from capital.
Bullish Signals
AbbVie reported revenue of $15 billion for the quarter, which is a 12.4% increase compared to the previous year.
The company beat analyst earnings estimates with EPS of $2.65 versus a consensus of $2.59.
Institutional interest remains strong with hedge funds and other institutional investors owning 70.23% of the company's stock.
AbbVie has established a consistent dividend history, offering a yield of 3.2% on its recent quarterly payout.
The company successfully expanded its revenue base beyond analyst expectations of $14.72 billion.
Risk Factors
AbbVie's stock is trading below its 200-day moving average of $218.78, indicating potential short-term weakness relative to longer-term trends.
The company has a high payout ratio of 340.89%, which suggests the dividend is being paid from capital rather than current earnings.
AbbVie Inc. (NYSE: ABBV) presented new Phase 3 data from the CLL14 trial at the European Hematology Association 2026 Congress in Stockholm, showing that a fixed-duration combination of venetoclax and obinutuzumab significantly improved progression-free survival compared to chlorambucil plus obinutuzumab in previously untreated chronic lymphocytic leukemia patients.
Following a median follow-up of 9.2 years, the trial demonstrated a median progression-free survival of 6.4 years for the venetoclax and obinutuzumab regimen versus 3.2 years for the comparator group. This data supports the expanded European Commission authorization granted on May 29, 2026, allowing Venclyxto in combination with acalabrutinib or ibrutinib for adult patients.
Additionally, AbbVie received FDA approval on May 27, 2026, for DECNUPAZ (pivekimab sunirine-pvzy) to treat adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy. Clinical data from the Phase 1/2 CADENZA trial showed a composite complete response rate of 69.7% in newly diagnosed patients and 15.7% in relapsed or refractory cases.
These regulatory approvals and positive clinical outcomes reinforce AbbVie's position in oncology, offering targeted oral medication options with potential for time off treatment. The company continues to research, develop, manufacture, and commercialize medicines worldwide, though the article notes a separate editorial view favoring AI stocks over ABBV.
๐ CLL14 trial: Venetoclax + obinutuzumab showed 6.4-year median progression-free survival vs 3.2 years.
๐ช๐บ EU approved Venclyxto expansion for acalabrutinib/ibrutinib combos in previously untreated CLL on May 29, 2026.
๐ FDA approved DECNUPAZ for BPDCN with 69.7% composite complete response rate based on CADENZA trial data.
๐ Fixed-duration regimens offer targeted oral options and potential treatment breaks in first-line settings.
๐ฌ AbbVie expands oncology portfolio with approvals in CLL and ultra-rare hematologic malignancies.
๐ AbbVie presented Phase 3 CLL14 trial data showing venetoclax plus obinutuzumab achieved a median progression-free survival of 6.4 years versus 3.2 years for the comparator in previously untreated chronic lymphocytic leukemia.
๐ช๐บ The European Commission authorized an expanded label for Venclyxto on May 29, 2026, including use with acalabrutinib or ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia in the EU and EEA.
๐ The FDA approved DECNUPAZ (pivekimab sunirine-pvzy) on May 27, 2026, for treating adult patients with BPDCN based on Phase 1/2 CADENZA trial data showing a 69.7% composite complete response rate in newly diagnosed patients.
๐ The fixed-duration regimens support current standards of care and provide additional targeted oral medication options in the first-line setting, including potential for time off treatment.
๐ฌ AbbVie's oncology portfolio expands with approvals in chronic lymphocytic leukemia and ultra-rare hematologic malignancies, reinforcing its therapeutic focus.
Bullish Signals
FDA approved DECNUPAZ for adult BPDCN with limited options.
EU expanded Venclyxto label for CLL combo therapy.
CLL14 trial showed 6.4 vs 3.2 years progression-free survival.
Fixed-duration regimens offer treatment breaks and better quality of life.
Bullish Signals
AbbVie received FDA approval for DECNUPAZ (pivekimab sunirine-pvzy) for treating adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options.
The European Commission authorized an expanded label for Venclyxto to include use in combination with acalabrutinib or ibrutinib for previously untreated chronic lymphocytic leukemia, extending availability across the EU and EEA.
Phase 3 CLL14 trial data demonstrated a significant improvement in progression-free survival (6.4 years vs. 3.2 years) for venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab after a median follow-up of 9.2 years.
The new fixed-duration combination regimens support current standards of care and offer patients the potential for time off treatment, enhancing patient convenience and quality of life.
AbbVie (NYSE: ABBV) is described as an underrated growth story with CEO Robert A. Michael reporting that the company exceeded expectations in Q1 2026. Despite shares trading at $221.59, down 1.43% year-to-date, revenue accelerated by 12.4% year-over-year. Immunology revenue specifically hit $7.29 billion, driven by a 30.9% increase in Skyrizi and a 23.3% rise in Rinvoq.
The article highlights a market disconnect where investors penalize the stock due to a one-time $744 million acquired-in-process R&D charge that reduced net income by 45.96%. This charge, along with structural declines in Humira revenue (down 38.6%) and Imbruvica (down 24.7%), has caused shares to trade at a discount despite strong operational fundamentals and low volatility.
Analyst consensus targets the stock at $253.55, implying 14% upside, while the author's model projects a base case of $245.35 with an optimistic scenario reaching $301 by June 2030. Reaching $300 from current levels requires a 35.4% gain, achievable through continued growth in Skyrizi and Rinvoq, fading R&D charge noise, and sustained expansion in the neuroscience franchise.
Key drivers for the bullish case include Skyrizi crossing $5.01 billion in revenue last quarter and Qulipta growing 53.6%. The stock currently trades at a forward P/E of 17x against earnings growth of over 12%, suggesting it is undervalued relative to its operating margins above 32%. However, risks include faster-than-expected erosion in the legacy oncology franchise and potential mega-cap dampening effects.
AbbVie Inc. (ABBV) has successfully transitioned its revenue base, with Skyrizi and Rinvoq now exceeding the peak sales of its former blockbuster drug, Humira. The company is currently trading at a forward P/E ratio of 14.8x, which sits below the average for pharmaceutical peers. Management has provided guidance indicating double-digit growth in immunology sales through 2026.
Despite the strong franchise and defensive characteristics, the stock faces headwinds from high leverage, specifically approximately $52.3 billion in net debt, and ongoing risks related to pipeline execution. Consequently, the analyst rates ABBV as a 'hold,' suggesting that investors should only accumulate shares on market weakness rather than at current fair valuations.
The investment case for AbbVie rests on its combination of dividend income, a robust immunology franchise, and potential for multiple expansion in uncertain macroeconomic environments. However, the valuation is characterized as fair rather than cheap, tempering enthusiasm despite the quality of the underlying business model.
๐ Skyrizi and Rinvoq surpass Humira peak sales.
๐ฐ Stock trades at 14.8x forward P/E below peers.
๐ Management guides double-digit immunology growth through 2026.
โ ๏ธ High leverage with $52.3 billion in net debt.
๐ Analysts rate stock 'hold' advising accumulation on weakness.
๐ Skyrizi and Rinvoq have surpassed Humira's peak sales, successfully replacing lost revenue.
๐ฐ The stock trades at a forward P/E of 14.8x, below the pharmaceutical peer average.
๐ Management guides for double-digit immunology sales growth through 2026.
โ ๏ธ High leverage is evident with approximately $52.3 billion in net debt.
๐ก๏ธ The company offers a defensive investment case with strong dividend yield.
๐ Analyst rates the stock as a 'hold' advising accumulation only on weakness.
CNBC's 'Final Trades' segment highlighted four specific investment picks from various market professionals, with AbbVie (NYSE: ABBV) selected by Bill Baruch, founder and CIO of Blue Line Capital and Blue Creek Capital Management. The article notes that AbbVie shares rose 1% to settle at $227.23 during the trading session.
Supporting the bullish sentiment on AbbVie, the company recently announced on May 29 that the European Commission authorized an expanded label for its drug VENCLYXTOยฎ (venetoclax). This regulatory approval includes additional combinations for treating previously untreated chronic lymphocytic leukemia, marking a significant expansion in the drug's approved indications.
The broader CNBC 'Final Trades' segment also featured picks for UnitedHealth Group, Sabra Health Care, and Coca-Cola. Analysts Kevin Fischbeck of B of A Securities upgraded UnitedHealth to Buy with a higher price target, while Coca-Cola saw its operating margins expand to 35% and organic revenue climb by 10% in the first quarter.
Despite the inclusion of other tickers like Sabra Health Care and UnitedHealth Group in the same article, the substantive news regarding AbbVie centers on the specific regulatory win for venetoclax and the endorsement from Bill Baruch. The stock's positive price movement aligns with these developments.
๐ Bill Baruch selected AbbVie as his final CNBC trade.
๐ฅ AbbVie got EU approval for VENCLYXTO in chronic lymphocytic leukemia.
๐ Shares rose 1% to close at $227.23 after news.
๐ฐ New label expands drug utility and potential revenue streams.
๐ Bill Baruch, founder and CIO of Blue Line Capital and Blue Creek Capital Management, selected AbbVie Inc. (NYSE: ABBV) as his final trade on CNBC.
๐ฅ On May 29, AbbVie received European Commission authorization to expand the label for VENCLYXTOยฎ (venetoclax) to include new combinations for previously untreated chronic lymphocytic leukemia.
๐ AbbVie shares rose 1% to close at $227.23 during the trading session following the news and analyst coverage.
๐ฐ The regulatory approval expands the drug's utility in treating a specific form of blood cancer, potentially opening new revenue streams for the oncology portfolio.
๐ CNBC's 'Final Trades' segment also highlighted positive momentum for Coca-Cola, UnitedHealth Group, and Sabra Health Care, though AbbVie was the primary focus of this specific ticker analysis.
Bullish Signals
Bill Baruch gives AbbVie a strong buy recommendation.
European Commission authorizes expanded VENCLYXTOยฎ label for CLL.
AbbVie received a strong buy recommendation from Bill Baruch, a prominent figure in the investment community managing Blue Line Capital and Blue Creek Capital Management.
The European Commission has officially authorized an expanded label for VENCLYXTOยฎ (venetoclax), allowing it to be used with additional combinations for previously untreated chronic lymphocytic leukemia.
AbbVie shares demonstrated positive momentum, rising 1% to settle at $227.23 during the session.
The regulatory expansion of venetoclax represents a significant milestone in the company's oncology pipeline, validating its R&D efforts in blood cancer treatments.
AbbVie announced on June 8, 2026, that it will present new clinical data across its blood cancer portfolio at the European Hematology Association (EHA) 2026 Congress in Stockholm. The presentation includes six oral and multiple poster sessions highlighting advancements in multiple myeloma, follicular lymphoma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, acute myeloid leukemia, and amyloidosis. Key investigational compounds featured include etentamig (ABBV-383), EPKINLY (epcoritamab-bysp), VENCLEXTA (venetoclax), and DECNUPAZ (pivekimab sunirine-pvzy).
Data from the EPCORE FL-1 trial demonstrated that epcoritamab combined with lenalidomide and rituximab achieved higher overall response rates in follicular lymphoma subgroups compared to standard therapy, with 96.5% response in low-risk patients versus 84.8%. In relapsed large B-cell lymphoma, epcoritamab monotherapy showed a statistically significant improvement in progression-free survival versus chemoimmunotherapy, with a hazard ratio of 0.74 and 24-month PFS of 30% compared to 13%.
Additional studies presented include final results from the CLL14 trial showing efficacy of venetoclax-obinutuzumab in previously untreated chronic lymphocytic leukemia, real-world data from the REVIVE study on venetoclax-based therapy for AML, and early-phase data for etentamig in multiple myeloma and amyloidosis. The company emphasized its commitment to advancing innovative solutions to address challenges in treating blood cancers.
๐ AbbVie presents six oral blood cancer data at EHA 2026.
๐ Low-risk follicular lymphoma ORR reaches 96.5% with epcoritamab combo.
๐ DLBCL monotherapy PFS improves to 30% vs 13% for chemo.
๐งฌ CLL14 confirms venetoclax-obinutuzumab efficacy in untreated chronic lymphocytic leukemia.
๐ AbbVie presents new clinical data at EHA 2026 covering six oral presentations across multiple blood cancer indications.
๐ EPCORE FL-1 trial subgroup analysis shows epcoritamab + lenalidomide/rituximab achieves 96.5% ORR in low-risk follicular lymphoma vs 84.8% for comparator.
๐ EPCORE DLBCL-1 results show epcoritamab monotherapy improves PFS vs chemoimmunotherapy (HR 0.74) with 30% vs 13% 24-month PFS.
๐งฌ CLL14 trial final results confirm venetoclax-obinutuzumab efficacy in previously untreated chronic lymphocytic leukemia patients.
๐ฌ REVIVE study presents real-world management practices for venetoclax-based therapy in newly diagnosed AML patients unfit for intensive chemotherapy.
๐งช Etentamig (ABBV-383) data presented for relapsed/refractory multiple myeloma with prior BCMA exposure and amyloidosis.
๐ฉบ Pivekimab sunirine-pvzy efficacy data shown in blastic plasmacytoid dendritic cell neoplasm with skin involvement.
๐ค EPKINLY and VENCLEXTA are approved therapies being investigated for additional uses; etentamig and pivekimab remain investigational.
โ ๏ธ Epcoritamab arm reported higher rates of grade 3-4 infections (30% vs 12%) and COVID-19 (36% vs 11%) in DLBCL trial.
๐ Full abstracts available via PR Newswire link; presentations held June 8, 2026 at EHA Congress in Stockholm.
Bullish Signals
96.5% vs 84.8% ORR in low-risk EPCORE FL-1 subgroup.
PFS HR 0.74; p=0.0059 for epcoritamab monotherapy in EPCORE DLBCL-1.
Venetoclax-obinutuzumab effective in previously untreated CLL patients.
Sustained remissions beyond 4 years confirmed in EPCORE NHL-1.
Improved QoL with epcoritamab for high symptom burden patients.
Risk Factors
Higher grade 3-4 infections (30% vs 12%) and COVID-19 (36% vs 11%).
Grade 5 adverse events in 17% of epcoritamab patients.
No significant overall survival improvement (HR 0.96; p=0.28).
Etentamig and pivekimab sunirine-pvzy remain investigational with no EU approval.
Lower ORR in high-risk FLIPI patients (72.6%) vs low-risk (93.0%).
Bullish Signals
EPCORE FL-1 subgroup analysis shows numerically higher overall response rates with epcoritamab + lenalidomide/rituximab across risk groups (96.5% vs 84.8% in low-risk).
EPCORE DLBCL-1 demonstrates statistically significant PFS improvement for epcoritamab monotherapy vs chemoimmunotherapy (HR 0.74; p=0.0059).
CLL14 trial final results support venetoclax-obinutuzumab as effective regimen in previously untreated CLL patients.
Real-world REVIVE study provides practical insights into venetoclax-based therapy management for AML in chemotherapy-unfit patients.
Etentamig shows promise in relapsed/refractory multiple myeloma with prior BCMA exposure, including triple-class resistance.
Pivekimab sunirine-pvzy demonstrates activity in rare BPDCN with skin involvement, supporting first-line use potential.
Long-term follow-up from EPCORE NHL-1 trial confirms sustained remissions beyond 4 years with epcoritamab monotherapy.
EPCORE FL-1 data supports improved or preserved health-related quality of life in patients with high symptom burden.
Risk Factors
In EPCORE DLBCL-1, epcoritamab arm reported higher rates of grade 3-4 infections (30% vs 12%) and any-grade COVID-19 (36% vs 11%).
Grade 5 treatment-emergent adverse events occurred in 17% of epcoritamab patients vs 6% in comparator, largely due to severe COVID-19 cases.
EPCORE DLBCL-1 did not demonstrate statistically significant improvement in overall survival (HR 0.96; p=0.28).
Etentamig and pivekimab sunirine-pvzy remain investigational with no EU approval as of June 2026.
EPCORE FL-1 subgroup analysis noted lower ORR in high-risk FLIPI patients (93.0% vs 72.6%) compared to low-risk counterparts.
AbbVie announced on June 8, 2026, that it will present new clinical data across its blood cancer portfolio at the European Hematology Association (EHA) 2026 Congress in Stockholm. The presentation includes six oral and multiple poster sessions highlighting advancements in multiple myeloma, follicular lymphoma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, acute myeloid leukemia, and amyloidosis. Key focus areas include approved therapies like EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax), as well as investigational compounds such as etentamig (ABBV-383) and pivekimab sunirine-pvzy.
Significant efficacy data was presented for epcoritamab in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma. A subgroup analysis of the Phase 3 EPCORE FL-1 trial showed numerically higher overall response rates (ORR) with the combination therapy compared to standard care across various risk subgroups, including patients with higher-risk disease features. The data also demonstrated consistent safety profiles across these subgroups with no new safety signals identified.
In relapsed or refractory large B-cell lymphoma, epcoritamab monotherapy showed a statistically significant improvement in progression-free survival versus investigator's choice of chemoimmunotherapy. The study reported a 24-month progression-free survival rate of 30% for the epcoritamab arm compared to 13% for the control group. However, the study did not demonstrate a statistically significant improvement in overall survival, though there was no OS detriment per pre-specified criteria.
Additional data covers venetoclax-based therapies in chronic lymphocytic leukemia based on genetic biomarkers, real-world management practices for acute myeloid leukemia, and efficacy of etentamig in multiple myeloma and amyloidosis. The company emphasized its commitment to pioneering innovative solutions to elevate standards of care and address pressing challenges in treating blood cancers through a robust pipeline of investigational and approved medicines.
๐ AbbVie presents new data at EHA 2026 Congress in Stockholm on June 8, 2026.
๐ Approved therapies include EPKINLY, VENCLEXTA, and DECNUPAZ for six blood cancer types.
๐ EPCORE FL-1 shows higher response rates; EPCORE DLBCL-1 shows improved survival vs chemoimmunotherapy.
๐งช Studies evaluate venetoclax, etentamig, and pivekimab sunirine-pvzy across various cancer indications.
๐ AbbVie is presenting new data at the European Hematology Association (EHA) 2026 Congress in Stockholm on June 8, 2026.
๐ฌ Six oral presentations and multiple posters highlight advancements across six blood cancer types: MM, FL, CLL, DLBCL, AML, and amyloidosis.
๐ Approved therapies featured include EPKINLY (epcoritamab-bysp), VENCLEXTA (venetoclax), and DECNUPAZ (pivekimab sunirine-pvzy).
๐ EPCORE FL-1 trial subgroup analysis shows numerically higher overall response rates for epcoritamab + lenalidomide + rituximab vs. standard care in high-risk follicular lymphoma patients.
โ๏ธ EPCORE DLBCL-1 trial results show statistically significant improvement in progression-free survival (30% vs 13% at 24 months) for epcoritamab monotherapy versus chemoimmunotherapy.
๐ฆ Higher rates of grade 3โ4 infections (30% vs 12%) and COVID-19 (36% vs 11%) were reported in the epcoritamab arm of the DLBCL trial.
๐งฌ GAIA/CLL13 trial results predict efficacy of venetoclax-based therapies in previously untreated CLL patients lacking specific genetic mutations.
๐ REVIVE study examines real-world management practices with venetoclax-based therapy for newly diagnosed AML patients unfit for intensive chemotherapy.
๐งช MONVISO study evaluates etentamig in relapsed/refractory multiple myeloma patients with prior BCMA-targeted therapy exposure.
๐ฉบ Updated results from M24-209 show longer-term safety and efficacy of etentamig monotherapy in light chain amyloidosis.
๐งฌ CADENZA study presents post-hoc analysis of pivekimab sunirine-pvzy efficacy in blastic plasmacytoid dendritic cell neoplasm with skin involvement.
๐ค EPKINLY is co-developed by Genmab and AbbVie, with AbbVie responsible for global commercialization outside the U.S. and Japan.
โ ๏ธ Important safety warnings include cytokine release syndrome, neurologic problems, infections, and low blood cell counts for epcoritamab.
๐ก๏ธ VENCLEXTA carries risks of tumor lysis syndrome, requiring specific hydration protocols and monitoring before and during treatment.
๐ Full abstracts and details on key presentations are available via the provided links in the press release.
Bullish Signals
96.5% vs 84.8% ORR in low-risk FL-1 subgroup.
30% 24-month PFS vs 13% with epcoritamab monotherapy.
No new safety signals observed in EPCORE FL-1.
Pipeline includes over 35 investigational medicines.
Etentamig shows promise in relapsed/refractory myeloma.
Risk Factors
DLBCL-1 trial showed no significant overall survival improvement for epcoritamab monotherapy.
Higher grade 3โ4 infections (30% vs 12%) and COVID-19 (36% vs 11%) in epcoritamab arm.
Grade 5 adverse events occurred more frequently (17% vs 6%), largely due to severe COVID-19.
EPKINLY carries serious risks including CRS, neurologic issues, and potential hospitalization or death.
Etentamig and pivekimab sunirine-pvzy are investigational and not approved in the EU.
EPKINLY safety warnings include CRS, neurologic problems, and Day 15/22 Cycle 1 hospitalization needs.
Bullish Signals
EPCORE FL-1 trial subgroup analysis demonstrates numerically higher overall response rates (96.5% vs 84.8% in low-risk; 93.0% vs 72.6% in high-risk) for epcoritamab combination therapy compared to standard care.
EPCORE DLBCL-1 trial shows statistically significant improvement in progression-free survival with epcoritamab monotherapy (HR 0.74), achieving 30% 24-month PFS versus 13% for chemoimmunotherapy.
No new safety signals were observed across subgroups in the EPCORE FL-1 trial, indicating consistent tolerability of the epcoritamab combination therapy.
Venetoclax-based therapies show predicted efficacy in CLL patients based on genetic biomarkers, offering potential for personalized treatment approaches.
Real-world data from the REVIVE study provides insights into managing venetoclax-based therapy for AML patients who cannot tolerate intensive chemotherapy.
Etentamig shows promise in relapsed/refractory multiple myeloma even after prior exposure to BCMA-targeted therapies, addressing a critical unmet need.
Longer-term safety and efficacy data for etentamig in amyloidosis supports its potential as a durable treatment option for this rare disease.
AbbVie's robust pipeline includes more than 35 investigational medicines across blood cancers and solid tumors, demonstrating strong R&D commitment.
Risk Factors
EPCORE DLBCL-1 trial did not demonstrate a statistically significant improvement in overall survival for epcoritamab monotherapy versus chemoimmunotherapy.
Higher rates of grade 3โ4 infections (30% vs 12%) and any-grade COVID-19 (36% vs 11%) were reported in the epcoritamab arm of the DLBCL trial.
Grade 5 treatment-emergent adverse events occurred more frequently in the epcoritamab arm (17% vs 6%), largely attributable to severe COVID-19 cases.
EPKINLY carries serious safety risks including cytokine release syndrome, neurologic problems, and infections that may lead to hospitalization or death.
VENCLEXTA poses a risk of tumor lysis syndrome, which can cause kidney failure and requires strict hydration and monitoring protocols.
Etentamig and pivekimab sunirine-pvzy are investigational therapies not approved in the EU, limiting immediate market access for these candidates.
Safety warnings for EPKINLY include risks of CRS and neurologic problems that may require step-up dosing schedules and hospitalization on Day 15 or 22 of Cycle 1.
AbbVie Inc. (NYSE: ABBV) is a global biopharmaceutical powerhouse with a market capitalization exceeding $400 billion, founded in 2013 as a spinoff from Abbott Laboratories. The company focuses on innovative treatments for immunology, oncology, virology, and neurology, anchored by its top-selling drug Humira and newer immunology products Rinvoq and Skyrizi, which are gaining significant market traction.
The stock has recently fluctuated between $226 and $230, reflecting active investor interest with daily trading volumes exceeding 6 million shares. A key attraction for investors is the company's robust dividend yield of approximately 3.05%, supported by a consistent history of increasing payments that provides stability during market volatility.
AbbVie faces competition from major players like Bristol Myers Squibb and Pfizer, particularly regarding Humira's patent expiration and biosimilar pressure. However, the company is diversifying its portfolio with Rinvoq showing 60% year-over-year sales growth and investing heavily in R&D for a pipeline targeting oncology and neurodegenerative diseases.
Analysts from firms like Goldman Sachs and Morgan Stanley have recently upgraded their ratings on AbbVie due to strong cash flow and a diverse pipeline. While risks include potential revenue declines from Humira's loss of exclusivity, the company's global expansion strategy and focus on chronic disease treatments position it for long-term growth.
๐ Market cap exceeds $400 billion in healthcare sector.
๐ Humira sales hit $20B despite biosimilar competition.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)